Beta Pharma, Inc. is an emerging specialty pharmaceutical company dedicated to the discovery, development, and commercialization of innovative late stage therapies targeting oncology.
Beta Pharma, Inc., originally named Beta Chemicals, Inc., was founded at the Science Park Campus of Yale in 1996 as a contract research organization providing custom synthesis services to biotechnology and pharmaceutical companies. Using profits from the CRO business, Beta Chemicals, Inc. evolved into Beta Pharma, Inc. and in 1998 initiated its first drug discovery project. The first major breakthrough came in 2002 with the synthesis of a novel EGFR tyrosine kinase inhibitor (“TKI”), icotinib. Icotinib is a 1st generation EGFR TKI for the treatment of EGFR-mutation positive advanced non-small-cell lung cancer (“NSCLC”).
Taking an innovative approach to drug development, Beta Pharma, Inc. partnered with investors to pursue development of icotinib in China. In 2011, the CFDA granted icotinib HCl marketing approval under the brand name Conmana®. Since its commercial approval, icotinib has gained over a third of the market share in lung cancer therapies, with over 40,000 patients treated.
Since the success of icotinib, Beta Pharma’s Research and Development Team continues to develop a fully integrated drug discovery platform with a robust pipeline of oncology research projects.
Beta Chemicals, Inc. Founded
Science Park, Campus of Yale
Beta Pharma, Inc. Founded
Synthesis of Icotinib Hydrochloride (EGFR Tyrosine Kinase Inhibitor)
Beta Pharma, Inc. Partners with Investors in China to Develop Icotinib
CFDA Grants Icotinib Marketing Approval (Brand Name Commana®)
Beta Pharma, Inc. Opens New Headquarters
Princeton, New Jersey
Beta Pharma, Inc. Laboratory Facility Completed
Monmouth Junction, New Jersey
Synthesis of BPI-7711 and BPI-1178
BPI-7711 Chinese CTA Filed